Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorChang Gung Memorial Hospital
About this trial
This study aims to determine whether people living with HIV (PLHIV) with suboptimal medical adherence can achieve better viral suppression with long-acting antiretrovirals (LA) compared to all-oral antiretrovirals.
Eligibility criteria
Qualifiers
Willing to sign the written informed consent form for male and female participants aged 18 and above.
At the time of enrollment, diagnosed with HIV infection for a minimum of 12 months.
Under oral antiretroviral treatment (ART), which can be irregular or interrupted, with the most recent viral load ≥ 200 copies/mL.
Body weight ≥ 35Kg.
Disqualifiers
For those currently undergoing oral antiretroviral therapy, who have started or restarted oral ART for less than six consecutive months before screening.
Previously undergone HIV drug resistance testing and known to have resistance mutations to either cabotegravir or rilpivirine.
Unable to commit to maintaining contact with the research team throughout the study.
Individuals who cannot receive treatment for hepatitis B during the period of transitioning to long-acting injections, if they are hepatitis B carriers.
Trial design
Treatments tested in this trial
- cabotegravir/rilpivirine (600mg/ 900mg)
- Antiretroviral Combinations
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Chang Gung Memorial Hospital
Lead sponsor
Taoyuan General Hospital
Collaborator
Source ClinicalTrials.gov